Although previous work on HE4 has primarily focused on its clinical utility as a tumor biomarker, increasing evidence has suggested that HE4 may have diagnostic potential in other clinical settings, including lung adenocarcinomas (18), renal fibrosis (8) and cystic fibrosis (9). Here, WFDC2 is linked to renal fibrosis.